Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2012  |  Volume : 8  |  Issue : 1  |  Page : 40--45

CYP 2D6 polymorphism: A predictor of susceptibility and response to chemoradiotherapy in head and neck cancer


Pragya Shukla1, Deepak Gupta1, Mohan Chand Pant2, Devendra Parmar3 
1 Department of Radiation Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, India
2 Department of Radiation Oncology, Chattrapatti Shahuji Maharaj Medical University, Lucknow, India
3 Developmental Toxicology Division, Indian Institute of Toxicology Research (Formerly: Industrial Toxicology Research Centre), Council CSIR, Lucknow, India

Correspondence Address:
Pragya Shukla
Department of Radiation Oncology, Tata Memorial Centre, Mumbai
India

Aims: A major problem in cancer pharmacology is the unpredictability of the outcome of therapy, both in terms of tumor response and host toxicity. Pharmacogenetic variability associated with the drug metabolizing enzyme systems is a major determinant of variations in these outcomes. Materials and Methods: A case-control study of 100 male cases of head and neck squamous cell carcinoma and equal number of healthy controls was conducted. Genomic DNA isolated from blood samples collected from controls and patients was studied by PCR-RFLP technique for CYP2D6 polymorphism. All patients received three cycles of cisplatinum-based sequential chemoradiotherapy. Results: The increased frequency of variant genotypes was associated with a statistically significant increase in the risk in the cases both in CYP2D6*4 and *10. The effect of interaction of the risk modifiers such as cigarette smoking or tobacco chewing or alcohol drinking with the CYP2D6 genotypes in the controls and patients was found to be significant. Response to therapy in patients with variant genotypes of CYP2D6 (CYP2D6*4 and CYP2D6*10) and treated with radio and chemotherapy regimen was poor. Conclusions: Functional enzyme deficiencies due to polymorphism in CYPs are not only important in enhancing susceptibility to head and neck squamous cell carcinoma but also in determining chemotherapeutic response.


How to cite this article:
Shukla P, Gupta D, Pant MC, Parmar D. CYP 2D6 polymorphism: A predictor of susceptibility and response to chemoradiotherapy in head and neck cancer.J Can Res Ther 2012;8:40-45


How to cite this URL:
Shukla P, Gupta D, Pant MC, Parmar D. CYP 2D6 polymorphism: A predictor of susceptibility and response to chemoradiotherapy in head and neck cancer. J Can Res Ther [serial online] 2012 [cited 2019 Oct 21 ];8:40-45
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2012;volume=8;issue=1;spage=40;epage=45;aulast=Shukla;type=0